1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Canada Infectious Diagnostics Market Outlook to 2021

Canada Infectious Diagnostics Market Outlook to 2021

  • August 2015
  • -
  • Global Data
  • -
  • 68 pages

Canada Infectious Diagnostics Market Outlook to 2021

Summary

GlobalData’s new report, "Canada Infectious Diagnostics Market Outlook to 2021", provides key market data on the Canada Infectious Diagnostics market. The report provides value, in millions of US dollars within market segments - Hepatitis Viruses, Retroviruses, Infectious Diagnostics Multiple Parameters Panels, Bacteriology, Nucleic Acid Testing Instruments, Other Virology, Infectious Diagnostics Rapid Tests & POC and Parasitology & Mycology.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Infectious Diagnostics market includes Hepatitis Viruses, Retroviruses, Infectious Diagnostics Multiple Parameters Panels, Bacteriology, Nucleic Acid Testing Instruments, Other Virology, Infectious Diagnostics Rapid Tests & POC and Parasitology & Mycology.
- Annualized market revenues (USD million) data for each of the market categories. Data is provided from 2007 to 2014 and forecast to 2021.
- 2014 company shares and distribution shares data for Infectious Diagnostics market.
- Global corporate-level profiles of key companies operating within the Canada Infectious Diagnostics market.
- Key players covered include Siemens Healthcare, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Hologic, Inc., Qiagen N.V., Becton, Dickinson and Company, Danaher Corporation and Alere Inc..

Reasons to buy

- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Table Of Contents

Canada Infectious Diagnostics Market Outlook to 2021
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 What Is This Report About? 6
2.2 Infectious Diagnostics Market Segmentation 6
2.3 Definitions of Markets Covered in the Report 7
3 Infectious Diagnostics Market, Canada 9
3.1 Infectious Diagnostics Market, Canada, Revenue ($m), 2007-2014 9
3.2 Infectious Diagnostics Market, Canada, Revenue ($m), 2014-2021 11
3.2.1 Infectious Diagnostics Rapid Tests and POC Market, Canada, Revenue ($m), by Segment, 2007-2014 13
3.2.2 Infectious Diagnostics Rapid Tests and POC Market, Canada, Revenue ($m), by Segment, 2014-2021 15
3.3 Infectious Diagnostics Market, Canada, Distribution Share by Revenue ($m), 2013-2014 17
3.4 Infectious Diagnostics Market, Canada, Company Share by Revenue ($m), 2014 18
4 Overview of Key Companies in Canada, Infectious Diagnostics Market 20
4.1 Qiagen N.V. 20
4.1.1 Company Overview 20
4.2 Abbott Laboratories 20
4.2.1 Company Overview 20
4.3 Hologic, Inc. 20
4.3.1 Company Overview 20
4.4 F. Hoffmann-La Roche Ltd. 21
4.4.1 Company Overview 21
4.5 Becton, Dickinson and Company 21
4.5.1 Company Overview 21
4.6 Siemens Healthcare 21
4.6.1 Company Overview 21
4.7 bioMerieux S.A. 22
4.7.1 Company Overview 22
4.8 Alere Inc. 22
4.8.1 Company Overview 22
4.9 Bio-Rad Laboratories, Inc. 22
4.9.1 Company Overview 22
5 Infectious Diagnostics Market Pipeline Products 23
6 Financial Deals Landscape 34
6.1 Debt Offerings 34
6.1.1 SQI Diagnostics Completes Second and Final Tranche of Private Placement of Debentures for USD1.3 Million 34
6.2 Equity Offerings 35
6.2.1 SQI Diagnostics Raises USD2.2 Million In in First Tranche of Private Placement of Shares 35
6.2.2 Spectral Diagnostics Raises USD4.7 Million in Second Tranche of Private Placement of Shares 36
6.3 Partnerships 38
6.3.1 Vivione Biosciences Enters into Distribution Agreement with Trillium Diagnostics 38
6.3.2 PAML Enters into Co-Development Agreement with Axela 39
6.3.3 Biocartis Enters into Licensing and Development Agreement with Microbiome 40
6.4 Venture Financing 41
6.4.1 Fio Raises USD0.7 Million in Venture Financing 41
7 Recent Developments 42
7.1 Corporate Communications 42
7.1.1 Jun 22, 2015: InVivo Therapeutics Receives Notice of Allowance on Patent Covering Broader Compositions for Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells 42
7.1.2 Jun 18, 2015: Dutch hospital acquires 1,000th Agility, Elekta's radiotherapy beam-shaping technology for treating cancer 43
7.1.3 Jun 17, 2015: Newly FDA-Approved Device for Stroke Prevention Available at Mercy 44
7.1.4 Mar 03, 2015: SQI Diagnostics Appoints Chief Financial Officer 45
7.1.5 Nov 04, 2014: MedMira Names Robyn Cook As Chief Corporate Officer 45
7.1.6 Oct 02, 2014: 3-V Biosciences To Present Clinical And Preclinical Data For FASN Inhibitors At EORTC-NCI-AACR 2014 46
7.1.7 Sep 29, 2014: SQI Diagnostics Announces New Chairman of Board of Directors 47
7.1.8 Sep 24, 2014: Spectral announces board changes 47
7.1.9 Sep 17, 2014: SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 48
7.2 Financial Announcements 48
7.2.1 Jun 17, 2015: Derma Sciences Announces Medicare Coverage Reinstated For MEDIHONEY Products with Reimbursable Codes by Centers for Medicare and Medicaid Services 48
7.2.2 May 21, 2015: SQI Diagnostics Reports Second Quarter Financial Results 49
7.2.3 May 13, 2015: Spectral Announces First Quarter 2015 Results 51
7.2.4 May 09, 2015: Shanghai MicroPort Orthopedics Hosts First SuperPath Online Symposium 51
7.2.5 Mar 25, 2015: Spectral Announces Fourth Quarter and Fiscal 2014 Results 52
7.2.6 Mar 20, 2015: MedMira Reports Second Quarter Financial Results 53
7.2.7 Feb 26, 2015: SQI Diagnostics Reports First Quarter Financial Results 53
7.2.8 Dec 31, 2014: MicroPort Completes First Implantation of Reewarm18 55
7.2.9 Dec 24, 2014: MedMira Reports First Quarter Results 56
7.2.10 Dec 17, 2014: SQI Diagnostics Reports Fourth Quarter and Fiscal 2014 Results 56
7.2.11 Nov 28, 2014: MedMira Reports 2014 Fourth Quarter And Year End Financial Results 58
7.2.12 Nov 24, 2014: Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 59
7.2.13 Nov 13, 2014: Spectral Announces Third Quarter 2014 Results 60
7.2.14 Aug 13, 2014: Spectral Announces Second Quarter, 2014 Results 61
7.3 Other Significant Developments 62
7.3.1 Jan 28, 2015: Two of MedMira's Multiplo Tests Procured for UNAIDS Program in Central Asia 62
7.3.2 Dec 16, 2014: Spectral Announces Effective Date of Name Change 62
7.3.3 Dec 15, 2014: SQI Diagnostics Wins Additional Business from UK-based Customer 63
7.4 Strategy And Business Planning 64
7.4.1 Jul 20, 2015: MedMira Opens US Subsidiary in Atlanta, GA 64
8 Appendix 65
8.1 Research Methodology 66
8.1.1 Coverage 66
8.1.2 Secondary Research 66
8.1.3 Primary Research 67
8.1.4 Company Share Analysis 67
8.1.5 Distribution Share Analysis 67
8.2 GlobalData Consulting 67
8.3 Contact Us 68
8.4 Disclaimer 68

1.1 List of Tables
Table 1: Infectious Diagnostics Market, Canada, Revenue ($m), USD Constant, Historic, 2007-2014 10
Table 2: Infectious Diagnostics Market, Canada, Revenue ($m), USD Constant, Forecast, 2014-2021 12
Table 3: Infectious Diagnostics Rapid Tests and POC Market, Canada, Revenue ($m), USD Constant, Historic, 2007-2014 14
Table 4: Infectious Diagnostics Rapid Tests and POC Market, Canada, Revenue ($m), USD Constant, Forecast, 2014-2021 16
Table 5: Infectious Diagnostics Market, Canada, Distribution Share by Revenue ($m), USD Constant, 2013-2014 17
Table 6: Infectious Diagnostics Market, Canada, Company Share by Revenue ($m), USD Constant, 2014 19
Table 7: Infectious Diagnostics Market Pipeline Products 23
Table 8: SQI Diagnostics Completes Second and Final Tranche of Private Placement of Debentures for USD1.3 Million 34
Table 9: SQI Diagnostics Raises USD2.2 Million In in First Tranche of Private Placement of Shares 35
Table 10: Spectral Diagnostics Raises USD4.7 Million in Second Tranche of Private Placement of Shares 36
Table 11: Vivione Biosciences Enters into Distribution Agreement with Trillium Diagnostics 38
Table 12: PAML Enters into Co-Development Agreement with Axela 39
Table 13: Biocartis Enters into Licensing and Development Agreement with Microbiome 40
Table 14: Fio Raises USD0.7 Million in Venture Financing 41

1.2 List of Figures
Figure 1: Infectious Diagnostics Market, Canada, Revenue ($m), USD Constant, Historic, 2007-2014 9
Figure 2: Infectious Diagnostics Market, Canada, Revenue ($m), USD Constant, Forecast, 2014-2021 11
Figure 3: Infectious Diagnostics Rapid Tests and POC Market, Canada, Revenue ($m), USD Constant, Historic, 2007-2014 13
Figure 4: Infectious Diagnostics Rapid Tests and POC Market, Canada, Revenue ($m), USD Constant, Forecast, 2014-2021 15
Figure 5: Infectious Diagnostics Market, Canada, Company Share (%) 2014 18

Companies Mentioned
Qiagen N.V.
Abbott Laboratories
Hologic, Inc.
F. Hoffmann-La Roche Ltd.
Becton, Dickinson and Company
Siemens Healthcare
bioMerieux S.A.
Alere Inc.
Bio-Rad Laboratories, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.